Market Research Logo

Overactive Bladder - Pipeline Review, H2 2015

Overactive Bladder - Pipeline Review, H2 2015

Summary

Global Markets Direct’s, ‘Overactive Bladder - Pipeline Review, H2 2015’, provides an overview of the Overactive Bladder’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Overactive Bladder, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Overactive Bladder and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Overactive Bladder
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Overactive Bladder and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Overactive Bladder products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Overactive Bladder pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
Reasons to buy
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Overactive Bladder
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Overactive Bladder pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


Introduction
Global Markets Direct Report Coverage
Overactive Bladder Overview
Therapeutics Development
Pipeline Products for Overactive Bladder - Overview
Pipeline Products for Overactive Bladder - Comparative Analysis
Overactive Bladder - Therapeutics under Development by Companies
Overactive Bladder - Therapeutics under Investigation by Universities/Institutes
Overactive Bladder - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Overactive Bladder - Products under Development by Companies
Overactive Bladder - Products under Investigation by Universities/Institutes
Overactive Bladder - Companies Involved in Therapeutics Development
Addex Therapeutics Ltd
Allergan Plc
AltheRx Pharmaceuticals, Inc.
Asahi Kasei Pharma Corp.
Astellas Pharma Inc.
Dong-A Socio Group
FemmePharma Global Healthcare, Inc.
Ferring International Center S.A.
Hydra Biosciences, Inc.
Ion Channel Innovations, LLC
Ipsen S.A.
Jeil Pharmaceutical Co., Ltd.
Laboratorios SALVAT S.A.
Lipella Pharmaceuticals, Inc.
Merck & Co., Inc.
Mezzion Pharma Co. Ltd.
MI.TO. Technology S.r.L.
NeuroSearch A/S
Recordati S.p.A.
Sanofi
Takeda Pharmaceutical Company Limited
TARIS BioMedical, Inc.
TheraVida, Inc.
Toray Industries, Inc.
Overactive Bladder - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
(mirabegron + solifenacin succinate) - Drug Profile
Product Description
Mechanism of Action
R&D Progress
(solifenacin succinate + tamsulosin hydrochloride) - Drug Profile
Product Description
Mechanism of Action
R&D Progress
abobotulinumtoxin A - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ADX-71441 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
DA-8010 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
FE-999309 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
HC-067047 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
mirabegron ER - Drug Profile
Product Description
Mechanism of Action
R&D Progress
NS-19504 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
onabotulinumtoxin A - Drug Profile
Product Description
Mechanism of Action
R&D Progress
oxybutynin chloride - Drug Profile
Product Description
Mechanism of Action
R&D Progress
oxybutynin hydrochloride - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Peptide to Antagonize PACAP Receptor for CNS and Overactive Bladder - Drug Profile
Product Description
Mechanism of Action
R&D Progress
pVAX-hSlo - Drug Profile
Product Description
Mechanism of Action
R&D Progress
REC-0438 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
SAR-244181 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
senrebotase - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecule to Antagonize Neurokinin-1 Receptor for Overactive Bladder - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecules to Agonize Beta3-Adrenoceptor for Anxiety, Depression and Overactive Bladder - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecules to Antagonize EP1 Receptor for Overactive Bladder - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecules to Antagonize TRPM8 for Overactive Bladder and Pain - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecules to Antagonize TRPV1 for Overactive Bladder - Drug Profile
Product Description
Mechanism of Action
R&D Progress
solabegron hydrochloride - Drug Profile
Product Description
Mechanism of Action
R&D Progress
solifenacin succinate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
solifenacin succinate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
tacrolimus - Drug Profile
Product Description
Mechanism of Action
R&D Progress
TAR-302 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
tarafenacin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
THVD-201 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
THVD-202 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
udenafil - Drug Profile
Product Description
Mechanism of Action
R&D Progress
vibegron - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Overactive Bladder - Recent Pipeline Updates
Overactive Bladder - Dormant Projects
Overactive Bladder - Discontinued Products
Overactive Bladder - Product Development Milestones
Featured News & Press Releases
Jun 15, 2015: NeXeption Forms New Company Velicept Therapeutics Intends to Merge with AltheRx Pharmaceuticals to Advance Solabegron for the Treatment of Overactive Bladder
May 17, 2015: Mirabegron As Add-On Treatment To Solifenacin Therapy Demonstrated Superior Results To Solifenacin Monotherapy In BESIDE Trial
May 05, 2015: Astellas Announces New Data To Be Presented During Late Breaking Plenary Session At AUA Annual Meeting
Dec 08, 2014: Lipella’s Liposome Formulation of Botulinum Toxin (LP-09) Superior to Placebo for Overactive Bladder Symptoms in Double-Blind Trial
Apr 08, 2014: Positive Clinical Trial Results of Topical Botulinum Toxin for Overactive Bladder
Oct 17, 2013: AltheRx Pharmaceuticals is Granted U.S. Patent for Use of Solabegron in Combination with Antimuscarinics for the Treatment of Overactive Bladder
Jul 03, 2013: Impax Laboratories Confirms Patent Challenge Relating to Generic TOVIAZ 4 mg and 8 mg
May 21, 2013: Addex Validates Potential Efficacy Biomarker For Phase I Trial Of ADX71441
May 17, 2013: Astellas's Betmiga Obtains NICE Recommendation For Restricted Use In Treatment Of Overactive Bladder
May 07, 2013: Astellas Pharma Presents Clinical Data On Myrbetriq At American Urological Association Annual Meeting
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Overactive Bladder, H2 2015
Number of Products under Development for Overactive Bladder - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Number of Products under Development by Companies, H2 2015 (Contd..1)
Number of Products under Investigation by Universities/Institutes, H2 2015
Comparative Analysis by Late Stage Development, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Development, H2 2015
Products under Development by Companies, H2 2015
Products under Development by Companies, H2 2015 (Contd..1)
Products under Development by Companies, H2 2015 (Contd..2)
Products under Investigation by Universities/Institutes, H2 2015
Overactive Bladder - Pipeline by Addex Therapeutics Ltd, H2 2015
Overactive Bladder - Pipeline by Allergan Plc, H2 2015
Overactive Bladder - Pipeline by AltheRx Pharmaceuticals, Inc., H2 2015
Overactive Bladder - Pipeline by Asahi Kasei Pharma Corp., H2 2015
Overactive Bladder - Pipeline by Astellas Pharma Inc., H2 2015
Overactive Bladder - Pipeline by Dong-A Socio Group, H2 2015
Overactive Bladder - Pipeline by FemmePharma Global Healthcare, Inc., H2 2015
Overactive Bladder - Pipeline by Ferring International Center S.A., H2 2015
Overactive Bladder - Pipeline by Hydra Biosciences, Inc., H2 2015
Overactive Bladder - Pipeline by Ion Channel Innovations, LLC, H2 2015
Overactive Bladder - Pipeline by Ipsen S.A., H2 2015
Overactive Bladder - Pipeline by Jeil Pharmaceutical Co., Ltd., H2 2015
Overactive Bladder - Pipeline by Laboratorios SALVAT S.A., H2 2015
Overactive Bladder - Pipeline by Lipella Pharmaceuticals, Inc., H2 2015
Overactive Bladder - Pipeline by Merck & Co., Inc., H2 2015
Overactive Bladder - Pipeline by Mezzion Pharma Co. Ltd., H2 2015
Overactive Bladder - Pipeline by MI.TO. Technology S.r.L., H2 2015
Overactive Bladder - Pipeline by NeuroSearch A/S, H2 2015
Overactive Bladder - Pipeline by Recordati S.p.A., H2 2015
Overactive Bladder - Pipeline by Sanofi, H2 2015
Overactive Bladder - Pipeline by Takeda Pharmaceutical Company Limited, H2 2015
Overactive Bladder - Pipeline by TARIS BioMedical, Inc., H2 2015
Overactive Bladder - Pipeline by TheraVida, Inc., H2 2015
Overactive Bladder - Pipeline by Toray Industries, Inc., H2 2015
Assessment by Monotherapy Products, H2 2015
Assessment by Combination Products, H2 2015
Number of Products by Stage and Target, H2 2015
Number of Products by Stage and Mechanism of Action, H2 2015
Number of Products by Stage and Route of Administration, H2 2015
Number of Products by Stage and Molecule Type, H2 2015
Overactive Bladder Therapeutics - Recent Pipeline Updates, H2 2015
Overactive Bladder - Dormant Projects, H2 2015
Overactive Bladder - Dormant Projects (Contd..1), H2 2015
Overactive Bladder - Dormant Projects (Contd..2), H2 2015
Overactive Bladder - Dormant Projects (Contd..3), H2 2015
Overactive Bladder - Dormant Projects (Contd..4), H2 2015
Overactive Bladder - Discontinued Products, H2 2015
Overactive Bladder - Discontinued Products (Contd..1), H2 2015
List of Figures
Number of Products under Development for Overactive Bladder, H2 2015
Number of Products under Development for Overactive Bladder - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Products, H2 2015
Assessment by Monotherapy Products, H2 2015
Assessment by Combination Products, H2 2015
Number of Products by Top 10 Targets, H2 2015
Number of Products by Stage and Top 10 Targets, H2 2015
Number of Products by Top 10 Mechanism of Actions, H2 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
Number of Products by Routes of Administration, H2 2015
Number of Products by Stage and Routes of Administration, H2 2015
Number of Products by Molecule Types, H2 2015
Number of Products by Stage and Molecule Types, H2 2015

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report